Advanced development of human mutant IDH1 inhibitors (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)

这个合作团队-由NCI，CBC/NExT，ESTA和NCATS的团队组成-旨在通过发现用于抗癌适应症的突变IDH 1的新型抑制剂来建立以前的研究。 作为一个中心，NCGC与NIH和校外研究人员建立并保持了110多个积极的合作关系，促进了整个人类疾病领域的药物发现工作。 这些努力已经导致了数十个高通量筛选和一些药物化学活动，以进一步改善筛选命中，为我们的合作者和一般研究社区提供出版物和各种有前途的小分子探针和线索。 此外，NCGC还致力于推进多项信息化举措，以更好地利用现有的药物和疾病靶点信息，并为公众提供易于获取的资源，进一步促进人类疾病新疗法的开发。

This collaborative team - composed of groups from NCI, CBC/NExT, UNC and NCATS - aims to build on previous research by uncovering novel inhibitors of mutant IDH1 for anticancer indications. As a center, the NCGC has fostered and maintained over 110 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.